New Directions in Managing Dyslipidemia

Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disea...

Full description

Saved in:
Bibliographic Details
Published in:Journal for nurse practitioners 2019-01, Vol.15 (1), p.73-79.e2
Main Author: Palmer, Carrie
Format: Article
Language:English
Subjects:
Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Diabetes
Disease management
Disease prevention
Drug therapy
dyslipidemia
Lipoproteins
Liver diseases
Metabolic disorders
Morbidity
Mortality
Nurse practitioners
Patients
PCSK9 inhibitor
Recurrent
statin
Statins
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53
cites cdi_FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53
container_end_page 79.e2
container_issue 1
container_start_page 73
container_title Journal for nurse practitioners
container_volume 15
creator Palmer, Carrie
description Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disease, or are statin intolerant. Recent updates give guidance on prevention of atherosclerotic cardiovascular disease in all patients, including those for whom statin therapy is contraindicated or insufficient. Other classes of medications, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, can lower low-density lipoprotein cholesterol and may also improve cardiovascular outcomes. This report explores dyslipidemia management guidelines, reviews the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, and provides recommendations for nurse practitioners. •Atherosclerotic cardiovascular disease remains a leading cause of death in the United States.•Statins are the mainstay of therapy to reduce atherosclerotic cardiovascular disease,•Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are recommended second-line agents.
doi_str_mv 10.1016/j.nurpra.2018.08.033
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2161279180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1555415518306603</els_id><sourcerecordid>2161279180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouH78Aw8FD55ak06SphdBdv2CVS8K3kKaTJeU3bYmu8r-e7OuZ2GYmcP7vsM8hFwwWjDK5HVX9JswBlOUlKmCpgI4IBOmKpVToT4O0y6EyHnqx-Qkxo5SUBL4hFy94Hc28wHt2g99zHyfPZveLHy_yGbbuPSjd7jy5owctWYZ8fxvnpL3-7u36WM-f314mt7OcwvA13ltpEOoQCpsnHUgOBUMBTXcNk3tkEtZS9O0FjmUHLGlErByleBcWUABp-RynzuG4XODca27YRP6dFKXTLKyqpmiScX3KhuGGAO2egx-ZcJWM6p3SHSn90j0DommqQCS7WZvw_TBl8ego_XYW3S_ALQb_P8BPzeHazg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2161279180</pqid></control><display><type>article</type><title>New Directions in Managing Dyslipidemia</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>ScienceDirect Freedom Collection 2022-2024</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><source>Sociology Collection</source><creator>Palmer, Carrie</creator><creatorcontrib>Palmer, Carrie</creatorcontrib><description>Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disease, or are statin intolerant. Recent updates give guidance on prevention of atherosclerotic cardiovascular disease in all patients, including those for whom statin therapy is contraindicated or insufficient. Other classes of medications, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, can lower low-density lipoprotein cholesterol and may also improve cardiovascular outcomes. This report explores dyslipidemia management guidelines, reviews the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, and provides recommendations for nurse practitioners. •Atherosclerotic cardiovascular disease remains a leading cause of death in the United States.•Statins are the mainstay of therapy to reduce atherosclerotic cardiovascular disease,•Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are recommended second-line agents.</description><identifier>ISSN: 1555-4155</identifier><identifier>EISSN: 1878-058X</identifier><identifier>DOI: 10.1016/j.nurpra.2018.08.033</identifier><language>eng</language><publisher>Philadelphia: Elsevier Inc</publisher><subject>Atherosclerosis ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Diabetes ; Disease management ; Disease prevention ; Drug therapy ; dyslipidemia ; Lipoproteins ; Liver diseases ; Metabolic disorders ; Morbidity ; Mortality ; Nurse practitioners ; Patients ; PCSK9 inhibitor ; Recurrent ; statin ; Statins ; Triglycerides</subject><ispartof>Journal for nurse practitioners, 2019-01, Vol.15 (1), p.73-79.e2</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright Elsevier Limited Jan 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53</citedby><cites>FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2161279180/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2161279180?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,12846,21394,21395,27924,27925,30999,33611,34530,43733,44115,74221,74639</link.rule.ids></links><search><creatorcontrib>Palmer, Carrie</creatorcontrib><title>New Directions in Managing Dyslipidemia</title><title>Journal for nurse practitioners</title><description>Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disease, or are statin intolerant. Recent updates give guidance on prevention of atherosclerotic cardiovascular disease in all patients, including those for whom statin therapy is contraindicated or insufficient. Other classes of medications, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, can lower low-density lipoprotein cholesterol and may also improve cardiovascular outcomes. This report explores dyslipidemia management guidelines, reviews the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, and provides recommendations for nurse practitioners. •Atherosclerotic cardiovascular disease remains a leading cause of death in the United States.•Statins are the mainstay of therapy to reduce atherosclerotic cardiovascular disease,•Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are recommended second-line agents.</description><subject>Atherosclerosis</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Disease management</subject><subject>Disease prevention</subject><subject>Drug therapy</subject><subject>dyslipidemia</subject><subject>Lipoproteins</subject><subject>Liver diseases</subject><subject>Metabolic disorders</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Nurse practitioners</subject><subject>Patients</subject><subject>PCSK9 inhibitor</subject><subject>Recurrent</subject><subject>statin</subject><subject>Statins</subject><subject>Triglycerides</subject><issn>1555-4155</issn><issn>1878-058X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2S</sourceid><recordid>eNp9kE1LxDAQhoMouH78Aw8FD55ak06SphdBdv2CVS8K3kKaTJeU3bYmu8r-e7OuZ2GYmcP7vsM8hFwwWjDK5HVX9JswBlOUlKmCpgI4IBOmKpVToT4O0y6EyHnqx-Qkxo5SUBL4hFy94Hc28wHt2g99zHyfPZveLHy_yGbbuPSjd7jy5owctWYZ8fxvnpL3-7u36WM-f314mt7OcwvA13ltpEOoQCpsnHUgOBUMBTXcNk3tkEtZS9O0FjmUHLGlErByleBcWUABp-RynzuG4XODca27YRP6dFKXTLKyqpmiScX3KhuGGAO2egx-ZcJWM6p3SHSn90j0DommqQCS7WZvw_TBl8ego_XYW3S_ALQb_P8BPzeHazg</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Palmer, Carrie</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ASE</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HEHIP</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201901</creationdate><title>New Directions in Managing Dyslipidemia</title><author>Palmer, Carrie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Atherosclerosis</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Disease management</topic><topic>Disease prevention</topic><topic>Drug therapy</topic><topic>dyslipidemia</topic><topic>Lipoproteins</topic><topic>Liver diseases</topic><topic>Metabolic disorders</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Nurse practitioners</topic><topic>Patients</topic><topic>PCSK9 inhibitor</topic><topic>Recurrent</topic><topic>statin</topic><topic>Statins</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palmer, Carrie</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Sociology Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Sociology Database (ProQuest)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal for nurse practitioners</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palmer, Carrie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Directions in Managing Dyslipidemia</atitle><jtitle>Journal for nurse practitioners</jtitle><date>2019-01</date><risdate>2019</risdate><volume>15</volume><issue>1</issue><spage>73</spage><epage>79.e2</epage><pages>73-79.e2</pages><issn>1555-4155</issn><eissn>1878-058X</eissn><abstract>Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disease, or are statin intolerant. Recent updates give guidance on prevention of atherosclerotic cardiovascular disease in all patients, including those for whom statin therapy is contraindicated or insufficient. Other classes of medications, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, can lower low-density lipoprotein cholesterol and may also improve cardiovascular outcomes. This report explores dyslipidemia management guidelines, reviews the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, and provides recommendations for nurse practitioners. •Atherosclerotic cardiovascular disease remains a leading cause of death in the United States.•Statins are the mainstay of therapy to reduce atherosclerotic cardiovascular disease,•Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are recommended second-line agents.</abstract><cop>Philadelphia</cop><pub>Elsevier Inc</pub><doi>10.1016/j.nurpra.2018.08.033</doi></addata></record>
fulltext fulltext
identifier ISSN: 1555-4155
ispartof Journal for nurse practitioners, 2019-01, Vol.15 (1), p.73-79.e2
issn 1555-4155
1878-058X
language eng
recordid cdi_proquest_journals_2161279180
source Applied Social Sciences Index & Abstracts (ASSIA); ScienceDirect Freedom Collection 2022-2024; Social Science Premium Collection (Proquest) (PQ_SDU_P3); Sociology Collection
subjects Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Diabetes
Disease management
Disease prevention
Drug therapy
dyslipidemia
Lipoproteins
Liver diseases
Metabolic disorders
Morbidity
Mortality
Nurse practitioners
Patients
PCSK9 inhibitor
Recurrent
statin
Statins
Triglycerides
title New Directions in Managing Dyslipidemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A06%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Directions%20in%20Managing%20Dyslipidemia&rft.jtitle=Journal%20for%20nurse%20practitioners&rft.au=Palmer,%20Carrie&rft.date=2019-01&rft.volume=15&rft.issue=1&rft.spage=73&rft.epage=79.e2&rft.pages=73-79.e2&rft.issn=1555-4155&rft.eissn=1878-058X&rft_id=info:doi/10.1016/j.nurpra.2018.08.033&rft_dat=%3Cproquest_cross%3E2161279180%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c334t-9a6de37368ebdcd354051e50a4cbb9de46696abfce4324eef063e7d75448c3e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2161279180&rft_id=info:pmid/&rfr_iscdi=true